Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- Registration Number
- NCT00523991
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 457
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo Placebo Oral inhalation once daily of placebo matching tiotropium via handihaler tiotropium tiotropium Oral inhalation once daily of 18mcg tiotropium via handihaler
- Primary Outcome Measures
Name Time Method Change From Baseline in Lung Function as Measured by the Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0-3h (AUC0-3h) baseline, week 24 Change = Week 24 Value - Baseline Value
- Secondary Outcome Measures
Name Time Method Trough Forced Expiratory Volume in 1 Second (FEV1)(Baseline) Baseline Trough FEV1 defined as the FEV1 measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FEV1 was the pre-treatment FEV1 measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (at Week 8) Baseline, week 8 Trough FEV1 defined as the FEV1 measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FEV1 was the pre-treatment FEV1 measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (at Week 16) Baseline, week 16 Trough FEV1 defined as the FEV1 measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FEV1 was the pre-treatment FEV1 measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (at Week 24) Baseline, week 24 Trough FEV1 defined as the FEV1 measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FEV1 was the pre-treatment FEV1 measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Peak Forced Expiratory Volume in 1 Second (Baseline) Baseline Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1.
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 8) Baseline, week 8 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 16) Baseline, week 16 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24) Baseline, week 24 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Forced Expiratory Volume in 1 Second (Baseline, Pre-dose) Baseline Forced expiratory volume in 1 second (baseline, pre-dose)
Forced Expiratory Volume in 1 Second (Baseline, 30 Minutes) baseline, 30 minutes Forced expiratory volume in 1 second (baseline, 30 minutes)
Forced Expiratory Volume in 1 Second (Baseline, 60 Minutes) baseline, 60 minutes Forced expiratory volume in 1 second (baseline, 60 minutes)
Forced Expiratory Volume in 1 Second (Baseline, 120 Minutes) Baseline, 120 minutes Forced expiratory volume in 1 second (baseline, 120 minutes)
Forced Expiratory Volume in 1 Second (Baseline, 180 Minutes) Baseline, 180 minutes Forced expiratory volume in 1 second (baseline, 180 minutes)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 8, Pre-dose) baseline, week 8, pre-dose Change from baseline in forced expiratory volume in 1 second (at week 8, pre-dose)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 8, 30 Minutes) Baseline, week 8, 30 minutes Change from baseline in forced expiratory volume in 1 second (at week 8, 30 minutes)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 8, 60 Minutes) baseline, week 8, 60 minutes Change from baseline in forced expiratory volume in 1 second (at week 8, 60 minutes)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 8, 120 Minutes) baseline, week 8, 120 minutes Change from baseline in forced expiratory volume in 1 second (at week 8, 120 minutes)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 8, 180 Minutes) baseline, week 8, 180 minutes Change from baseline in forced expiratory volume in 1 second (at week 8, 180 minutes)
Change From Baseline in Forced Expiratory Volume in 1 Second (at Week 16, Pre-dose) baseline, week 16, pre-dose Change from baseline in forced expiratory volume in 1 second (at week 16, pre-dose)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 16, 30 Minutes) Baseline, week 16, 30 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 16, 30 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 16, 60 Minutes) baseline, week 16, 60 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 16, 60 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 16, 120 Minutes) baseline, week 16, 120 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 16, 120 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 16, 180 Minutes) baseline, week 16, 180 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 16, 180 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24, Pre-dose) baseline, week 24, pre-dose Change from baseline in peak forced expiratory volume in 1 second (at week 24, pre-dose)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24, 30 Minutes) baseline, week 24, 30 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 24, 30 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24, 60 Minutes) baseline, week 24, 60 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 24, 60 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24, 120 Minutes) baseline, week 24, 120 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 24, 120 minutes)
Change From Baseline in Peak Forced Expiratory Volume in 1 Second (at Week 24, 180 Minutes) baseline, week 24, 180 minutes Change from baseline in peak forced expiratory volume in 1 second (at week 24, 180 minutes)
FVC AUC0-3 at Baseline baseline Forced vital capacity (FVC) area under the curve from 0-3 hours (AUC0-3h)
FVC AUC0-3 at Week 8 Minus Baseline baseline, week 8 Change from baseline in Forced vital capacity (FVC) area under the curve from 0-3 hours (AUC0-3h) (week 8)
FVC AUC0-3 at Week 16 Minus Baseline baseline, week 16 Change from baseline in Forced vital capacity (FVC) area under the curve from 0-3 hours (AUC0-3h)(week 16)
FVC AUC0-3 at Week 24 Minus Baseline baseline, week 24 Change from baseline in Forced vital capacity (FVC) area under the curve from 0-3 hours (AUC0-3h) (week 24)
Trough Forced Vital Capacity (Baseline) baseline Trough FVC defined as the FVC measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FVC was the pre-treatment FVC measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Vital Capacity (at Week 8) baseline, week 8 Trough FVC defined as the FVC measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FVC was the pre-treatment FVC measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Vital Capacity (at Week 16) baseline, week 16 Trough FVC defined as the FVC measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FVC was the pre-treatment FVC measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Change From Baseline in Trough Forced Vital Capacity (at Week 24) baseline, week 24 Trough FVC defined as the FVC measured at 10 minutes prior to the end of the dosing interval, approximately 24 hours post drug administration. Baseline FVC was the pre-treatment FVC measured at Week 0 in the morning 10 minutes prior to the administration of the first dose of the study medication.
Peak Forced Vital Capacity (FVC) (Baseline) baseline Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1.
Change From Baseline in Peak Forced Vital Capacity (at Week 8) baseline, week 8 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Change From Baseline in Peak Forced Vital Capacity (at Week 16) baseline, week 16 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Change From Baseline in Peak Forced Vital Capacity (at Week 24) baseline, week 24 Peak FEV1 defined as the maximum of the observed values over 30, 60, 120, and 180 minutes post-dose for FEV1. Peak response was defined as the change from baseline to the peak FEV1 value at the final visit.
Forced Vital Capacity (Baseline, Pre-dose) baseline Forced vital capacity (baseline, pre-dose)
Forced Vital Capacity (Baseline, 30 Minutes) baseline, 30 minutes Forced vital capacity (baseline, 30 minutes)
Forced Vital Capacity (Baseline, 60 Minutes) baseline, 60 minutes Forced vital capacity (baseline, 60 minutes)
Forced Vital Capacity (Baseline, 120 Minutes) baseline, 120 minutes Forced vital capacity (baseline, 120 minutes)
Forced Vital Capacity (Baseline, 180 Minutes) baseline, 180 minutes Forced vital capacity (baseline, 180 minutes)
Change From Baseline in Forced Vital Capacity (Week 8, Pre-dose) baseline, week 8, pre-dose Change from baseline in forced vital capacity (week 8, pre-dose)
Change From Baseline in Forced Vital Capacity (Week 8, 30 Minutes) baseline, week 8, 30 minutes Change from baseline in forced vital capacity (week 8, 30 minutes)
Change From Baseline in Forced Vital Capacity (Week 8, 60 Minutes) baseline, week 8, 60 minutes Change from baseline in forced vital capacity (week 8, 60 minutes)
Change From Baseline in Forced Vital Capacity (Week 8, 120 Minutes) baseline, week 8, 120 minutes Change from baseline in forced vital capacity (week 8, 120 minutes)
Change From Baseline in Forced Vital Capacity (Week 8, 180 Minutes) baseline, week 8, 180 minutes Change from baseline in forced vital capacity (week 8, 180 minutes)
Change From Baseline in Forced Vital Capacity (Week 16, Pre-dose) baseline, week 16, pre-dose Change from baseline in forced vital capacity (week 16, pre-dose)
Change From Baseline in Forced Vital Capacity (Week 16, 30 Minutes) baseline, week 16, 30 minutes Change from baseline in forced vital capacity (week 16, 30 minutes)
Change From Baseline in Forced Vital Capacity (Week 16, 60 Minutes) baseline, week 16, 60 minutes Change from baseline in forced vital capacity (week 16, 60 minutes)
Change From Baseline in Forced Vital Capacity (Week 16, 120 Minutes) baseline, week 16, 120 minutes Change from baseline in forced vital capacity (week 16, 120 minutes)
Change From Baseline in Forced Vital Capacity (Week 16, 180 Minutes) baseline, week 16, 180 minutes Change from baseline in forced vital capacity (week 16, 180 minutes)
Change From Baseline in Forced Vital Capacity (Week 24, Pre-dose) baseline, week 24, pre-dose Change from baseline in forced vital capacity (week 24, pre-dose)
Change From Baseline in Forced Vital Capacity (Week 24, 30 Minutes) baseline, week 24, 30 minutes Change from baseline in forced vital capacity (week 24, 30 minutes)
Change From Baseline in Forced Vital Capacity (Week 24, 60 Minutes) baseline, week 24, 60 minutes Change from baseline in forced vital capacity (week 24, 60 minutes)
Change From Baseline in Forced Vital Capacity (Week 24, 120 Minutes) baseline, week 24, 120 minutes Change from baseline in forced vital capacity (week 24, 120 minutes)
Change From Baseline in Forced Vital Capacity (Week 24, 180 Minutes) baseline, week 24, 180 minutes Change from baseline in forced vital capacity (week 24, 180 minutes)
Albuterol Use p.r.n. (Baseline) baseline Number of days that participants used albuterol prn per week
Change From Baseline in Albuterol Use p.r.n. - (Week 4) baseline, week 4 Difference in number of days that participants used albuterol prn per week between week 4 and baseline
Change From Baseline in Albuterol Use p.r.n. - (Week 8) baseline, week 8 Difference in number of days that participants used albuterol prn per week between week 8 and baseline
Change From Baseline in Albuterol Use p.r.n. -(Week 12) baseline, week 12 Difference in number of days that participants used albuterol prn per week between week 12 and baseline
Change From Baseline in Albuterol Use p.r.n. - (Week 16) baseline, week 16 Difference in number of days that participants used albuterol prn per week between week 16 and baseline
Change From Baseline in Albuterol Use p.r.n. -(Week 20) baseline, week 20 Difference in number of days that participants used albuterol prn per week between week 20 and baseline
Change From Baseline in Albuterol Use p.r.n. - (Week 24) baseline, week 24 Difference in number of days that participants used albuterol prn per week between week 24 and baseline
Number of Participants With Categorical Scores on Physician's Global Assessment (Baseline) baseline The physician's global assessment reflected the physician's opinion of the participant's overall clinical condition with respect to COPD. The evaluation was based on the participant's use of concomitant medications, as well as the number and severity of COPD exacerbations and related emergency room visits and/or hospitalizations since the last visit. The frequency and severity of symptoms ( cough, dyspnea, wheezing) and the impact of these on the participant's ability to exercise were considered.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Number of Participants With Categorical Scores on Physician's Global Assessment (Week 12) week 12 The physician's global assessment reflected the physician's opinion of the participant's overall clinical condition with respect to COPD. The evaluation was based on the participant's use of concomitant medications, as well as the number and severity of COPD exacerbations and related emergency room visits and/or hospitalizations since the last visit. The frequency and severity of symptoms ( cough, dyspnea, wheezing) and the impact of these on the participant's ability to exercise were considered.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Number of Participants With Categorical Scores on Physician's Global Assessment (Week 24) week 24 The physician's global assessment reflected the physician's opinion of the participant's overall clinical condition with respect to COPD. The evaluation was based on the participant's use of concomitant medications, as well as the number and severity of COPD exacerbations and related emergency room visits and/or hospitalizations since the last visit. The frequency and severity of symptoms ( cough, dyspnea, wheezing) and the impact of these on the participant's ability to exercise were considered.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Number of Participants With Categorical Scores on Patient's Global Assessment (Baseline) baseline The patient's global assessment was based on the subject's need to take additional medications for breathing, their need for emergency room or hospital visits for COPD, and severity and amount of coughing, wheezing, and/or breathing discomfort experienced, and the impact of these symptoms on the subject's ability to exercise and perform daily activities.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Number of Participants With Categorical Scores on Patient's Global Assessment (Week 12) week 12 The patient's global assessment was based on the subject's need to take additional medications for breathing, their need for emergency room or hospital visits for COPD, and severity and amount of coughing, wheezing, and/or breathing discomfort experienced, and the impact of these symptoms on the subject's ability to exercise and perform daily activities.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Number of Participants With Categorical Scores on Patient's Global Assessment (Week 24) week 24 The patient's global assessment was based on the subject's need to take additional medications for breathing, their need for emergency room or hospital visits for COPD, and severity and amount of coughing, wheezing, and/or breathing discomfort experienced, and the impact of these symptoms on the subject's ability to exercise and perform daily activities.
Range: 1-2 = Poor, 3-4 = Fair 5-6 = Good, 7-8 = Excellent.Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Baseline) baseline WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment.
Absenteeism, Presenteeism, Work productivity loss, Activity Impairment Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment.Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 4) baseline, week 4 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 4 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 8) baseline, week 8 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 8 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 12) baseline, week 12 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 12 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 16) baseline, week 16 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 16 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 20) baseline, week 20 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 20 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment Due to Health (Week 24) baseline, week 24 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 24 and baseline.
Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health baseline WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment.
Absenteeism, Presenteeism, Work productivity loss, Activity Impairment Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment.Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 4) baseline, week 4 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 4 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 8) baseline, week 8 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 8 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 12) baseline, week 12 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 12 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 16) baseline, week 16 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 16 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 20) baseline, week 20 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 20 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Impairment While Working Due to Health (Week 24) baseline, week 24 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 24 and baseline.
Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Baseline) baseline WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment.
Absenteeism, Presenteeism, Work productivity loss, Activity Impairment Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment.Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 20) baseline, week 20 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 20 and baseline.
Change From Baseline in Physical Activity (Moderate or Higher Intensity; Week 4) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 4 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 24) baseline, week 24 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 24 and baseline.
Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Baseline) baseline WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment.
Absenteeism, Presenteeism, Work productivity loss, Activity Impairment Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment.Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 4) baseline, week 4 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 4 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 8) baseline, week 8 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 8 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 12) baseline, week 12 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 12 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 4) baseline, week 4 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 4 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 8) baseline, week 8 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 8 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 16) baseline, week 16 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 16 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 20) baseline, week 20 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 20 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Work Time Missed Due to Health (Week 24) baseline, week 24 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 24 and baseline.
Physical Activity (Light Intensity; Baseline) in Logarithm of Average Time Spent in Minutes Per Day baseline Light intensity is less than three metabolic equivalents.
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithm.Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 12) baseline, week 12 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 12 and baseline.
Change From Baseline in Work Productivity as Assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire: Overall Work Impairment Due to Health (Week 16) baseline, week 16 WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Scores range from 0 to 100 for each of the above 4 types; higher scores indicate greater impairment. Difference refers to change in scale between week 16 and baseline.
Change From Baseline in Physical Activity (Light Intensity; Week 4) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 4 Light intensity is less than three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Light Intensity; Week 8) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 8 Light intensity is less than three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Light Intensity; Week 12) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 12 Light intensity defined as less than three metabolic equivalents.
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Light Intensity; Week 16) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 16 Light intensity is less than three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Light Intensity; Week 20) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 20 Light intensity is less than three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Light Intensity; Week 24) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 24 Light intensity is less than three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmPhysical Activity (Moderate or Higher Intensity; Baseline) in Logarithm of Average Time Spent in Minutes Per Day baseline Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Active Energy Expenditure (Week 4) baseline, week 4 The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Physical Activity (Moderate or Higher Intensity; Week 8) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 8 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Moderate or Higher Intensity; Week 12) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 12 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Moderate or Higher Intensity; Week 16) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 16 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmChange From Baseline in Physical Activity (Moderate or Higher Intensity; Week 24) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 24 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmNumber of Participants With Healthy Lifestyle (Week 4) week 4 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Number of Participants With Healthy Lifestyle (Baseline) baseline Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Active Energy Expenditure (Baseline) baseline The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Active Energy Expenditure (Week 8) baseline, week 8 The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Active Energy Expenditure (Week 12) baseline, week 12 The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Active Energy Expenditure (Week 16) baseline, week 16 The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Physical Activity (Moderate or Higher Intensity; Week 20) in Logarithm of Average Time Spent in Minutes Per Day baseline, week 20 Moderate or higher intensity is greater than or equal to three metabolic equivalents
Metabolic equivalent threshold (MET): Unit used to estimate the metabolic cost of physical activity, in terms of multiples of the subject's resting metabolic rate. One metabolic equivalent is, by convention, 3.5 ml of O2 uptake per minute per kilogram body weight, and theoretically approximates the resting metabolic rate.
ln in measure value unit means natural logarithmNumber of Participants With Healthy Lifestyle (Week 8) week 8 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Change From Baseline in Active Energy Expenditure (Week 20) baseline, week 20 The amount of energy (kcal/day) that a person uses while physically active.
Change From Baseline in Active Energy Expenditure (Week 24) baseline, week 24 The amount of energy (kcal/day) that a person uses while physically active.
Number of Steps Per Day (Baseline) baseline Number of steps per day (baseline)
Number of Participants With Healthy Lifestyle (Week 12) week 12 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Number of Participants With Healthy Lifestyle (Week 16) week 16 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Number of Participants With Healthy Lifestyle (Week 20) week 20 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Change From Baseline in Number of Steps Per Day (Week 24) baseline, week 24 Change from baseline in number of steps per day (week 24)
Number of Participants With Healthy Lifestyle (Week 24) week 24 Healthy lifestyle defined as 30 minutes of activity \> 3 metabolic equivalent levels for 70% of eligible days. Two categories: Yes, no
Change From Baseline in Number of Steps Per Day (Week 4) baseline, week 4 Change from baseline in number of steps per day (week 4)
Change From Baseline in Number of Steps Per Day(Week 8) baseline, week 8 Change from baseline in number of steps per day (week 8)
Change From Baseline in Number of Steps Per Day (Week 12) baseline, week 12 Change from baseline in Number of steps per day (week 12)
Change From Baseline in Number of Steps Per Day (Week 16) baseline, week 16 Change from baseline in number of steps per day (week 16)
Change From Baseline in Number of Steps Per Day (Week 20) baseline, week 20 Change from baseline in number of steps per day (week 20)
Trial Locations
- Locations (62)
205.365.1025 Boehringer Ingelheim Investigational Site
🇵🇹Amadora, Portugal
205.365.1107 Boehringer Ingelheim Investigational Site
🇨🇿Hradec Kralove, Czech Republic
205.365.1079 Boehringer Ingelheim Investigational Site
🇨🇿Neratovice, Czech Republic
205.365.1116 Boehringer Ingelheim Investigational Site
🇨🇿Pardubice, Czech Republic
205.365.1117 Boehringer Ingelheim Investigational Site
🇨🇿Praha 6, Czech Republic
205.365.1022 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
205.365.1077 Boehringer Ingelheim Investigational Site
🇨🇿Liberec, Czech Republic
205.365.1020 Boehringer Ingelheim Investigational Site
🇵🇹Coimbra, Portugal
205.365.44002 Boehringer Ingelheim Investigational Site
🇬🇧Garston, Watford, United Kingdom
205.365.44004 Boehringer Ingelheim Investigational Site
🇬🇧Warminster, United Kingdom
205.365.1003 Boehringer Ingelheim Investigational Site
🇺🇸Birmingham, Alabama, United States
205.365.1006 Boehringer Ingelheim Investigational Site
🇺🇸Rochester, Minnesota, United States
205.365.1010 Boehringer Ingelheim Investigational Site
🇺🇸Albuquerque, New Mexico, United States
205.365.1080 Boehringer Ingelheim Investigational Site
🇺🇸Charlotte, North Carolina, United States
205.365.1103 Boehringer Ingelheim Investigational Site
🇧🇪Gilly, Belgium
205.365.1057 Boehringer Ingelheim Investigational Site
🇧🇪Menen, Belgium
205.365.1041 Boehringer Ingelheim Investigational Site
🇨🇦Ste-Foy, Quebec, Canada
205.365.1122 Boehringer Ingelheim Investigational Site
🇺🇸Clarksburg, West Virginia, United States
205.365.1058 Boehringer Ingelheim Investigational Site
🇧🇪Yvoir, Belgium
205.365.1042 Boehringer Ingelheim Investigational Site
🇨🇦Vancouver, British Columbia, Canada
205.365.1104 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
205.365.1064 Boehringer Ingelheim Investigational Site
🇨🇿Cvikov, Czech Republic
205.365.1083 Boehringer Ingelheim Investigational Site
🇨🇿Praha 3, Czech Republic
205.365.1062 Boehringer Ingelheim Investigational Site
🇨🇿Praha 10, Czech Republic
205.365.1066 Boehringer Ingelheim Investigational Site
🇩🇪Berlin, Germany
205.365.1050 Boehringer Ingelheim Investigational Site
🇩🇪Ulm, Germany
205.365.1072 Boehringer Ingelheim Investigational Site
🇳🇱Etten Leur, Netherlands
205.365.1112 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
205.365.1115 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
205.365.1113 Boehringer Ingelheim Investigational Site
🇺🇦Simferopol, Ukraine
205.365.1052 Boehringer Ingelheim Investigational Site
🇩🇪Rüdersdorf, Germany
205.365.1055 Boehringer Ingelheim Investigational Site
🇩🇪Berlin, Germany
205.365.1004 Boehringer Ingelheim Investigational Site
🇺🇸Birmingham, Alabama, United States
205.365.1098 Boehringer Ingelheim Investigational Site
🇺🇸Jasper, Alabama, United States
205.365.1023 Boehringer Ingelheim Investigational Site
🇺🇸Palo Alto, California, United States
205.365.1012 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
205.365.1086 Boehringer Ingelheim Investigational Site
🇺🇸Bloomington, Minnesota, United States
205.365.1033 Boehringer Ingelheim Investigational Site
🇺🇸Pittsburgh, Pennsylvania, United States
205.365.1059 Boehringer Ingelheim Investigational Site
🇧🇪Leuven, Belgium
205.365.1061 Boehringer Ingelheim Investigational Site
🇨🇿Karlovy Vary, Czech Republic
205.365.1075 Boehringer Ingelheim Investigational Site
🇨🇿Strakonice, Czech Republic
205.365.1063 Boehringer Ingelheim Investigational Site
🇨🇿Tabor, Czech Republic
205.365.1067 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
205.365.1076 Boehringer Ingelheim Investigational Site
🇨🇿Usti nad Labem, Czech Republic
205.365.1054 Boehringer Ingelheim Investigational Site
🇩🇪Gelnhausen, Germany
205.365.1126 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
205.365.1127 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
205.365.1070 Boehringer Ingelheim Investigational Site
🇳🇱Enschede, Netherlands
205.365.1071 Boehringer Ingelheim Investigational Site
🇳🇱Spijkenisse, Netherlands
205.365.1069 Boehringer Ingelheim Investigational Site
🇳🇱Zutphen, Netherlands
205.365.1110 Boehringer Ingelheim Investigational Site
🇺🇦Kharkiv, Ukraine
205.365.1128 Boehringer Ingelheim Investigational Site
🇺🇦Dnipropetrovsk, Ukraine
205.365.44003 Boehringer Ingelheim Investigational Site
🇬🇧Harrow, United Kingdom
205.365.1114 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
205.365.1007 Boehringer Ingelheim Investigational Site
🇺🇸Rochester, New York, United States
205.365.1092 Boehringer Ingelheim Investigational Site
🇺🇸Kingsport, Tennessee, United States
205.365.1056 Boehringer Ingelheim Investigational Site
🇨🇦Kingston, Ontario, Canada
205.365.1125 Boehringer Ingelheim Investigational Site
🇺🇸San Diego, California, United States
205.365.1024 Boehringer Ingelheim Investigational Site
🇺🇸Lexington, Kentucky, United States
205.365.1108 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
205.365.1085 Boehringer Ingelheim Investigational Site
🇺🇸Omaha, Nebraska, United States
205.365.1118 Boehringer Ingelheim Investigational Site
🇺🇸Cincinnati, Ohio, United States